The transcatheter aortic valve replacement (TAVR) market in Japan is expected to exceed US$450m in 2025, driven by the increasing prevalence of aortic stenosis in elderly population, forecasts GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Transcatheter Aortic Valve Replacement (TAVR) (Cardiovascular) – Global Market Analysis and Forecast Model (COVID-19 Market Impact)’, reveals that Japan accounted for more than 60% of the Asia-Pacific (APAC) TAVR market in 2020. Edward Lifesciences Corp is the leading player in the TAVR market in Japan in 2020 with around 90% share.

Anusha Kaushik, Medical Devices Analyst at GlobalData, comments: “TAVR procedures are mostly performed in elderly population as they are more susceptible to aortic stenosis. In Japan, in elderly population, TAVR is more preferred over surgical aortic valve replacement (SAVR) for aortic stenosis by healthcare professionals due to its short hospital stay, less risk of exposure to infection as it is a ‘minimally invasive’ procedure.”

More than 43 million of the Japanese population is 60 and above and more than 18 million of the population is 75 and above. In Japan, TAVR procedures are mostly performed in the 75 years and above age group with fewer than 10% of patients treated with TAVR being below the age of 75 years. Based on GlobalData analysis, in Japan, the percentage of patients receiving TAVR that are under the age of 75 years is expected to increase to about 20% in the next five years.

Ms. Kaushik concludes: “Currently, TAVR is indicated for patients with severe symptomatic aortic valve stenosis. Expanding the TAVR indication to include mild aortic stenosis and moderate aortic stenosis will lead to higher patient pool eligible for receiving TAVR. Positive clinical trial results showcasing safety and effectiveness of TAVR devices, new device approvals, increased physician awareness and training are expected to drive the growth of TAVR market in Japan.”